Management of Cytopenias during Chronic Hepatitis C Therapy

Alyson N. Fox; Vinod K. Rustgi

doi:10.1002/9781444319590.ch15

Management of Cytopenias during Chronic Hepatitis C Therapy

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Combination therapy with peginterferon alfa and ribavirin is the mainstay of therapy for chronic hepatitis C. The use of these agents is often limited by adverse events, of which cytopenias are common. The development of haematological abnormalities often results in drug dose reduction or discontinuation, which limits efficacy of achieving virological outcomes. Management of these haematological abnormalities with growth factors offers the possibility of therapy continuation.

Original language	English (US)
Title of host publication	Clinical Dilemmas in Viral Liver Disease
Publisher	Wiley-Blackwell
Pages	65-69
Number of pages	5
ISBN (Print)	9781405179058
DOIs	https://doi.org/10.1002/9781444319590.ch15
State	Published - Mar 10 2010
Externally published	Yes

All Science Journal Classification (ASJC) codes

Medicine(all)

Keywords

Anaemia
Hepatitis C
Neutropenia
Peginterferon
Ribavirin
Thrombocytopenia

Access to Document

10.1002/9781444319590.ch15

Cite this

@inbook{46522b1096f8426eb5a6f9fe9c14dd86,

title = "Management of Cytopenias during Chronic Hepatitis C Therapy",

abstract = "Combination therapy with peginterferon alfa and ribavirin is the mainstay of therapy for chronic hepatitis C. The use of these agents is often limited by adverse events, of which cytopenias are common. The development of haematological abnormalities often results in drug dose reduction or discontinuation, which limits efficacy of achieving virological outcomes. Management of these haematological abnormalities with growth factors offers the possibility of therapy continuation.",

keywords = "Anaemia, Hepatitis C, Neutropenia, Peginterferon, Ribavirin, Thrombocytopenia",

author = "Fox, {Alyson N.} and Rustgi, {Vinod K.}",

year = "2010",

month = mar,

day = "10",

doi = "10.1002/9781444319590.ch15",

language = "English (US)",

isbn = "9781405179058",

pages = "65--69",

booktitle = "Clinical Dilemmas in Viral Liver Disease",

publisher = "Wiley-Blackwell",

address = "United States",

}

TY - CHAP

T1 - Management of Cytopenias during Chronic Hepatitis C Therapy

AU - Fox, Alyson N.

AU - Rustgi, Vinod K.

PY - 2010/3/10

Y1 - 2010/3/10

N2 - Combination therapy with peginterferon alfa and ribavirin is the mainstay of therapy for chronic hepatitis C. The use of these agents is often limited by adverse events, of which cytopenias are common. The development of haematological abnormalities often results in drug dose reduction or discontinuation, which limits efficacy of achieving virological outcomes. Management of these haematological abnormalities with growth factors offers the possibility of therapy continuation.

AB - Combination therapy with peginterferon alfa and ribavirin is the mainstay of therapy for chronic hepatitis C. The use of these agents is often limited by adverse events, of which cytopenias are common. The development of haematological abnormalities often results in drug dose reduction or discontinuation, which limits efficacy of achieving virological outcomes. Management of these haematological abnormalities with growth factors offers the possibility of therapy continuation.

KW - Anaemia

KW - Hepatitis C

KW - Neutropenia

KW - Peginterferon

KW - Ribavirin

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84886061864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886061864&partnerID=8YFLogxK

U2 - 10.1002/9781444319590.ch15

DO - 10.1002/9781444319590.ch15

M3 - Chapter

AN - SCOPUS:84886061864

SN - 9781405179058

SP - 65

EP - 69

BT - Clinical Dilemmas in Viral Liver Disease

PB - Wiley-Blackwell

ER -

Management of Cytopenias during Chronic Hepatitis C Therapy

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this